The FDA is phasing out animal testing and moving to more human-relevant methods. This was announced as one of Marty Makary’s ...

The first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the ...

At the heart of Demis Hassabis’ vision is the revolutionary impact AI could have on healthcare, particularly in accelerating ...

Scale-up is a common problem encountered in all forms of development across industries, and oral solid dose manufacturing ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

The Boao Lecheng International Medical Tourism Pilot Zone in Hainan province has released pricing for China's first batch of ...

In the face of such pressure, pharmaceutical companies are eager to reduce the cost of drug development so that consumer prices can be lowered without sacrificing profit margin. Fortunately ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

The Food and Drug Administration will create a national standard and timeline for the food industry to phase out all ...

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...

Andrei Georgescu of Vivodyne discusses key advantages of its humanized drug testing platform and the impact of the FDA’s ...

Ex-Google CEO Eric Schmidt warns AI could surpass human control by 2026. Discover the risks and opportunities of artificial ...